Biovica

We are excited about the strong DiviTum TKa results recently published in JCO Precision Oncology! 🎉 The study highlights the potential of longitudinal TKa monitoring in MBC and early BC to support treatment decisions. Read more: loom.ly/Wd6gNxY #bscm #divitum @onclive

Register for our upcoming Q2 Earnings call taking place: 18th December, 2025 at 15:00 CET. Register here: loom.ly/dFtLoL8 Presenters are: Anders Rylander, CEO Anders Morén, CFO #biovicb #investors #oncology #biomarker #pharma

At #SABCS25? Dec 10th, 5-6:30 PM CST, hear Dr. Mariya Rozenblit from Yale School of Medicine present. Read the Abstract PS2-09-28: loom.ly/Wxy5NX8 The #biomarker here: loom.ly/tAJuUX0 #biomarker #personalizedmedicine #divitum #bscm @onclive

At #SABCS25? Dec 10th, 5-6:30 PM CST, hear Dr. Elena Michaels from Mass General Brigham Cancer Institute present. Read the Abstract PS2-10-21: loom.ly/Wxy5NX8 The #biomarker here: loom.ly/tAJuUX0 #biomarker #personalizedmedicine #divitum #bscm @onclive

We’re excited to introduce the team representing us at SABCS25! They look forward to discussing our latest work with TKa—the breast cancer biomarker that measures cell proliferation. Submit a request to meet: loom.ly/1JqZvKA #SABSC25 #biomarker #bscm @onclive

We are proud that our SVP Hanna Ritzén is presenting at the upcoming 18th EBF. On Nov 18th, 2025: Join her at 11:10 AM local time. Read more about our biomarker DiviTum TKa here: loom.ly/c__nywg #EBF2025 #bioanalysisforum #divitum #precesionmedicine #oncology

Remember to register! Our upcoming Q1 Earnings call is taking place: 11th September, 2025 at 14:00 CET. Register here: loom.ly/hEIjkx4 Presenters are: Anders Rylander, CEO Anders Morén, CFO #biovicb #investors #oncology #biomarker #pharma

mailchi.mp/40dcedceb5db/turn… Start monitoring treatment response and tumor proliferation of your breast cancer patients today! In the US? Collect a small amount of blood and send it to Biovica in our pre-paid mailer. You will receive results in 2-4 days: divitum.com/contact/

Register for our upcoming Q1 Earnings call taking place: 11th September, 2025 at 14:00 CET. Register here: loom.ly/hEIjkx4 Presenters are: Anders Rylander, CEO Anders Morén, CFO #biovicb #investors #oncology #biomarker #pharma

New Interview from RedEye! How will Biovica use the proceeds? Where does Biovica stand with the newly signed partner agreements? Watch it on our website for investor relations. Read more on RedEye. #biovicb #investors #oncology #firstnorth

Today, we launch our DiviTum® Tka test for use in early breast cancer for patients in adjuvant therapy! It is available as a laboratory-developed test (LDT) from our CLIA-certified laboratory in the US. #Biovica #biomarker #bscm #divitum #precisionmedicine #breastcancer @onco

We have signed a new Pharma work order! 🎉 We are excited to receive yet another work order - the 4th contract from a leading Tier-1 pharma company. This time for 3 MSEK. Read More here: loom.ly/omXNDg4 #biovica #personalizedmedicine #biomarker #firstnorth

Biovicas innovation ligger bokstavligen i blodet biostock.se/2025/07/biovicas… #lightweb via @lightweb

Biovicas vd: ”Förr tog det månader. Nu tar det ett blodprov” biostock.se/2025/07/biovicas… #lightweb via @lightweb

Biovica granted new European patent! The patent will come into effect on July 16, 2025, in conjunction with its publication in the European Patent Bulletin. Read More: loom.ly/ay43Vvg #pharma #biomarker #oncology #immunooncology #biovicb #immunecheckpointinhibitor

REMINDER! Do not miss our Q4 Earnings call taking place: 18th June, 2025 at 15:00 CET. To register loom.ly/4oFPscU Presenters are: Anders Rylander, CEO Anders Morén, CFO #biovicb #investors #oncology #biomarker #pharma

A milestone in our growing customer base: we have signed an agreement with a fifth Tier-1 US biopharma company! 📣📢🔊 Read More on Biovica.com #biovica #personalizedmedicine #biomarker #firstnorth

Notice of extra general meeting in Biovica International AB! Monday 14 July 2025, at 10:00 CET at Baker McKenzie Advokatbyrå on Vasagatan 7, 101 23 Stockholm. To attend the general meeting, Click here: loom.ly/ay43Vvg #biovicb #investor #nasdaqfirstnorth

Biovica resolves on a rights issue of approximately SEK 80.1 million! 💵💶 The Board of Directors of Biovica has today approved by an EGM a new issue of A-shares and B-shares. Read the details on biovica.com #biovicb #investors #oncology #firstnorth

Biovica announces financial targets following key partnerships and commercial progress! 🎯💰💵💶🎗 Today, we have announced financial goals for the upcoming two fiscal years. Read the goals on biovica.com #biovicb #investors #oncology #firstnorth